Evidence map›Paper›PMID 39496938›Full record

ReviewCancer gene therapy2025

Role of non-coding RNA in lineage plasticity of prostate cancer.

Wenhui Tan, Changkai Xiao, Min Ma, Youhan Cao, Zhenguo Huang, Xiaolan Wang, Ran Kang, Zhenfa Li, Ermao Li

Abstract readReview
PubMed Publisher
In one paragraph

Review in Cancer gene therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Wenhui TanInstitute of Translational Medicine, Hengyang Medical College, University of South China, Hengyang, 421001, Hunan, China.
Changkai XiaoDepartment of Urology, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, 421001, Hunan, China.
Min MaInstitute of Translational Medicine, Hengyang Medical College, University of South China, Hengyang, 421001, Hunan, China.
Youhan CaoDepartment of Urology, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, 421001, Hunan, China.
Zhenguo HuangDepartment of Urology, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, 421001, Hunan, China.
Xiaolan WangDepartment of Urology, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, 421001, Hunan, China.
Ran KangDepartment of Urology, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, 421001, Hunan, China. rkdr2015@163.com.ORCID 0009-0003-6614-8171
Zhenfa LiAffiliated Hengyang Hospital of Hunan Normal University & Hengyang Central Hospital, Hengyang, 421001, Hunan, China. lizfa@163.com.
Ermao LiInstitute of Translational Medicine, Hengyang Medical College, University of South China, Hengyang, 421001, Hunan, China. liem2018@usc.edu.cn.ORCID 0000-0003-3159-1256

Funding

National Natural Science Foundation of China (National Science Foundation of China) 82303122
6 · The paper itself

Abstract

The treatment of prostate cancer (PCa) has made great progress in recent years, but treatment resistance always develops and can even lead to fatal disease. Exploring the mechanism of drug resistance is of great significance for improving treatment outcomes and developing biomarkers with predictive value. It is increasingly recognized that mechanism of drug resistance in advanced PCa is related to lineage plasticity and tissue differentiation. Specifically, one of the mechanisms by which castration-resistant prostate cancer (CRPC) cells acquire drug resistance and transform into neuroendocrine prostate cancer (NEPC) cells is lineage plasticity. NEPC is a subtype of PCa that is highly aggressive and lethal, with a median survival of only 7 months. With the development of high-throughput RNA sequencing technology, more and more non-coding RNAs have been identified, which play important roles in different diseases through different mechanisms. Several ncRNAs have shown great potential in PCa lineage plasticity and as biomarkers. In the review, the role of ncRNA in PCa lineage plasticity and its use as biomarkers were reviewed.

Indexed as

Prostatic NeoplasmsProstatic Neoplasms, Castration-ResistantRNA, UntranslatedAnimalsBiomarkers, TumorCell LineageCell PlasticityHumansMaleBiomarkers, TumorRNA, Untranslated

Identifiers

PMID39496938

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.